Philips and Diagnostics Development win European Union 'Horizon Prize - Better Use of Antibiotics'

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a leader in HealthTech, and Diagnostics Development, a P&M Venge company spin-off from Uppsala University (Sweden), have demonstrated a proof-of-concept for the rapid and reliable detection of bacterial infection. The test is based on Philips' Minicare I-20 handheld diagnostics platform and detects the human neutrophil lipocalin (HNL) biomarker in a single 'finger-prick' drop of blood. In recognition of the test's ability to distinguish between acute bacterial and viral infections, and thereby mitigate the unnecessary use of antibiotics, the two companies were awarded the European Union 'Horizon Prize - Better Use of Antibiotics' during a special award ceremony on the evening of February 6, 2017.

Antimicrobial agents - such as antibiotics - have dramatically reduced the number of deaths from infectious diseases since their introduction 70 years ago. However, through their overuse and misuse, many micro-organisms have become resistant to them. It is estimated that each year this growing antimicrobial resistance (AMR) causes around 25,000 deaths and accounts for over EUR 1.5 billion in healthcare costs and productivity losses in Europe alone, making it one of the greatest challenges facing society today. To boost development and bring new and innovative players to AMR research, the EU issued a prize for the individual or team that most effectively meets the following challenge: "to develop a rapid test that will allow healthcare providers to distinguish at the point of care between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without antibiotics".

"This prize is a great recognition of how collaboration can lead to innovative diagnostic solutions that improve patient care," said Marcel van Kasteel, CEO of Handheld Diagnostics at Philips. "The HNL program for detection of bacterial infections perfectly fits with our 'open platform' strategy of bringing innovative biomarker content onto the Minicare I-20 platform in order to offer healthcare professionals a panel of relevant tests for acute settings. Activities are ongoing to further develop the HNL test for eventual implementation in routine clinical practice.

"In various studies, HNL has demonstrated superior performance compared to biomarkers currently used to diagnose bacterial infection," said Per Venge, CEO of P&M Venge AB. "I am therefore very excited that we have been able to successfully demonstrate the detection of HNL on the Minicare I-20 using blood samples from patients with upper respiratory tract infections in the Uppsala University hospital, where within a few minutes patients with a bacterial infection could clearly be distinguished from those with viral infections or other conditions."

Based on Philips' proprietary biosensor technology, the Minicare I-20 handheld diagnostics platform is designed to detect multiple target molecules at very low concentrations in a single 'finger-prick' blood sample, and display the results on a handheld analyzer within minutes. Philips already has CE marking for its Minicare I-20 based cardiac troponin I (cTnI) blood test for the rapid point-of-care diagnosis of heart attack, and it is currently developing further tests for acute care settings.

Minicare I-20 is simple and easy to use by non-laboratory staff. The analyzer's built-in connectivity allows direct transfer of the data to laboratory and hospital information systems to update patient files, while integrated calibration and fail-safe functionalities ensure the robustness and accuracy needed for confident on-the-spot decision making.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries.

Most Popular Now

Mental Health Mobile Apps Are Effective …

When it comes to strengthening your mental or emotional health, would you trust an app? A trio of Brigham Young University health science researchers has published new research that says...

Virtual Reality for Bacteria

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a computer. The interdisciplinary team including...

Social Mobile Gaming Boosts Rehabilitati…

The researchers from Imperial have designed a video game called Balloon Buddies, which is a tool that enables those recovering from conditions such as a stroke to engage and play...

Open Call SC1-HCC-03-2018: Support to Fu…

Citizens in ageing populations wish to stay in their homes for as long as possible. They are however at risk of age related impairments such as poor health, cognitive impairment...

New Software can Verify Someone's Identi…

In the science-fiction movie Gattaca, visitors only clear security if a blood test and readout of their genetic profile matches the sample on file. Now, cheap DNA sequencers and custom...

Philips to Help Develop AI and Machine L…

Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, is pleased to be associated with the government's recently announced £4.7 billion Industrial Strategy Challenge Fund. Working with public...

Open Call SC1-HCC-05-2018: Support to a …

The Communication on the mid-term review of the implementation of the Digital Single Market Strategy (COM(2017)228) identified three priorities on digital transformation of health and care (DTHC): citizens' access to...

Roche to Acquire Viewics, Inc. to Provid…

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all...

Philips Expands its Radiology Solutions …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired US-based start-up company Analytical Informatics, Inc., complementing its own innovation initiatives to...

Philips Expands its Population Health Ma…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired VitalHealth, a leading provider of cloud-based population health management solutions for the...

West of Scotland Creates Regional Portal

Scottish health boards covering a population of 2.2 million people are able to share patient information now that a two-year project to create a regional portal has been completed. Five...